MicroPort Scientific Corporation (00853.HK) announced on Sunday (October 25) that its board of directors has declared the following board changes, effective from October 22, 2026:
Dr. Chang Zhaohua has resigned as director and related positions due to other personal matters. Dr. Chang has confirmed to the company that he has no disagreement with the board, and there are no matters related to his resignation that need to be brought to the attention of shareholders. Dr. Chang will continue to serve the group as Chief Science Officer of the company, and will devote himself to promoting cutting-edge technological innovation and other related matters. The company hereby expresses its sincere gratitude to Dr. Chang for his diligent efforts and valuable contributions to the group.
Mr. Jonathan W. Chen has been appointed as an executive director, chief executive officer, and authorized representative of the company under Rule 3.05 of the Listing Rules, effective October 22, 2026. The board is committed to enhancing the company's corporate governance and strengthening its management structure. To this end, the following measures will be taken:
1) Enhancing corporate governance and authorization arrangements. The company will review its governance structure, the division of responsibilities and decision-making procedures between the board and the company's management, including authority allocation, authorization arrangements, and reporting mechanisms. As part of the review, the company will further improve its governance policies and guidelines, clearly specifying matters that must be approved by the board, including revoking any corporate governance structures and/or management organizations established or implemented without formal board approval, which must not continue. Any matter that should be approved by the board but is carried out without approval will be deemed unauthorized and must be reported to the board immediately. If there is any doubt as to whether a matter requires board approval or the scope of authorization, the matter should be submitted to the board for clarification before any action is taken.
2) Strengthening the management structure. With Mr. Chen's appointment as executive director and chief executive officer, the company will implement a management structure led by the chief executive officer, under which Mr. Chen will be accountable to and report directly to the board, and will be fully responsible for the company's daily management and operations. The company will also establish a president's office to assist Mr. Chen in fulfilling his management duties and to coordinate the work of relevant functional departments.
According to MicroPort's 2025 annual report disclosed on April 30, 2026: Dr. Chang Zhaohua, born in 1963, was the company's chairman, executive director, and chief executive officer. Dr. Chang has more than 35 years of experience in the medical device industry and currently serves as a professor at the School of Medical Instruments at the University of Shanghai for Science and Technology. Before founding Shanghai MicroPort Medical (Group) Co., Ltd. in 1998, Dr. Chang served from 1996 to 1997 as vice president of research and development at Endocare Inc., a medical device company headquartered in California, USA (which was delisted from Nasdaq in 2003). From 1990 to 1995, Dr. Chang held successive positions at Cryomedical Sciences Inc., a listed medical device company in Maryland, USA, including senior engineer, chief scientist, director of research and development, and vice president of engineering. Dr. Chang obtained a bachelor's degree in refrigeration engineering and a master's degree in cryogenic engineering from the University of Shanghai for Science and Technology in 1983 and 1985, respectively. Dr. Chang currently serves as a non-executive director and chairman of MicroPort Robotics-B (02252.HK, a subsidiary of the company); from November 3, 2023 to November 14, 2025, Dr. Chang served as a non-executive director and chairman of MicroPort NeuroTech (02172.HK). He also currently holds directorships in several subsidiaries of the group. He obtained a doctorate in biological sciences from Binghamton University, State University of New York, in 1992. Dr. Chang has published extensively in the field of biomedical science and holds dozens of patents in China and the United States.
In addition, according to the Hong Kong Stock Exchange's official website and its equity disclosure website, since the four MicroPort-linked Hong Kong stocks were suspended from trading on the same day, September 1, as of now: MicroPort Scientific (00853.HK) remains suspended; MicroPort CardioFlow-B (02160.HK), in which it holds 44.45% (as of December 19, 2025), remains suspended; MicroPort NeuroTech (02172.HK), in which it holds 38.61% (as of December 22, 2025), remains suspended; and MicroPort Robotics-B (02252.HK), in which it holds 45.63% (as of June 1, 2026), remains suspended.
Comments